{"name":"Grey Wolf Therapeutics","slug":"grey-wolf-therapeutics","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Part C - Safety expansion cohort in participants with axSpA","genericName":"Part C - Safety expansion cohort in participants with axSpA","slug":"part-c-safety-expansion-cohort-in-participants-with-axspa","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"Part C - Safety expansion cohort in participants with axSpA","genericName":"Part C - Safety expansion cohort in participants with axSpA","slug":"part-c-safety-expansion-cohort-in-participants-with-axspa","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE4xMHVKU1RITHdrZjVaUW1md05BUnU3UzhLMG82YXJHUWtDYnpMTDFEU051UjVWVlFDLTcyb3dpQTZQcTVnempQbmM0ekhjeVBPVlp2NDJyMHl1QllIR3ZF?oc=5","date":"2026-01-13","type":"trial","source":"nature.com","summary":"Therapeutic responses in patients with advanced NSCLC enrolled in early-phase clinical trials at MD Anderson - nature.com","headline":"Therapeutic responses in patients with advanced NSCLC enrolled in early-phase clinical trials at MD Anderson","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxQb3RSVFI3SFUzRmR1SUVaSkNfd0F2YzdlNmtVWWFVdkFNYnpkc0FPQkZVWHFvU0REaUJNemdmdkdaNmdQTmJIWHBSNHBqaEtLeWRSYXAwanRhVUpXM0ZtVGtZQTI4U3VoeWJZYjVibGpKTjhfZkRTa3hLWl9sYXpxWkozcmFSZHdTTzd4QUJRT0x3cFVwaUhxZmtrd2kyd1FfcXRN?oc=5","date":"2025-12-18","type":"pipeline","source":"Österreichische Akademie der Wissenschaften","summary":"ISA International Guest Lecture: Laurent Prodié - Österreichische Akademie der Wissenschaften","headline":"ISA International Guest Lecture: Laurent Prodié - Österreichische Akademie der Wissenschaften","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMicEFVX3lxTE50Q0VNeElPNnFXRXM3WkFrbGVsQkhwWWtxRXBTaF9iOUp2ZlY2QUFla1F0MFgwNEJBMDZRRHBxbmd5TFNTdVJNa2c2eFNvTG1PX0w2QjlyN3E3WTljcF9veEZmbnR5RjlEa1VyNXRRT3A?oc=5","date":"2025-10-25","type":"pipeline","source":"The Times","summary":"Ipsen, AstraZeneca and Greywolf lead winners at Pharma Industry Awards UK 2025 in association with Kuehne + Nagel - The Times","headline":"Ipsen, AstraZeneca and Greywolf lead winners at Pharma Industry Awards UK 2025 in association with Kuehne + Nagel","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxQdlNHYm83dXNJMHNkOXAtWEtWbmFYdmtUX1hTNlNNdEc4UGxfTHlGS1dJY0ZGc1NQZy1VV3ZVeHNlT0JlV0ZFWF94cjU4NnhXMzhNcVU0ZG9tZ3RsbWVFZUduTUF5UmJYSmhIa1NIX3ZsdEpEdTdtc3pfNEZrd1NXb1c2UlJia0J6NkJNX0I0bHRkRjVfV0VwdDRSRFI0NUZRU2Jmb2RldzVkRGhndXFoUVBaZnBXV3Z2d2tsUlpjVno?oc=5","date":"2025-08-14","type":"trial","source":"The Clinical Trial Vanguard","summary":"Greywolf Therapeutics Initiates Dosing of First-in-Class Autoimmunity Treatment - The Clinical Trial Vanguard","headline":"Greywolf Therapeutics Initiates Dosing of First-in-Class Autoimmunity Treatment","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3gFBVV95cUxQVk5wUkQ0ZlYzZVFtTmg4ZnMxaWUxTTVqNmRLYWRSbGdyS2tjbk82SWVxNkVrMkFhTUwyeFVwMXN1MzhkQkdyc2p2clRIWElzejlxSTRXQlI2Wk8wM3FCbXU2blItd1NJYUFrNVdtczFOeThwQjVfN2N0cjRZdXdMTlJuTE01Q3VwUS02VnRHeHE0RWJ4RVh3dXkxQjRjMkRFQllpUzczOVktbl83QTZ4SFpVVEtEZ3BBaHlvLWRhQ0tzUmtPYnlnby1Sc3BTZmJoT0RLWEpyeGdPaEh1TlE?oc=5","date":"2025-08-13","type":"pipeline","source":"BioSpace","summary":"Greywolf Therapeutics begins dosing of the first treatment to target the antigenic source of autoimmunity - BioSpace","headline":"Greywolf Therapeutics begins dosing of the first treatment to target the antigenic source of autoimmunity","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTFBKaHA0NG5sNXMzNVA0TmZGZFV6Ri1keWpYUmUwLTIyMFpNWmVOcDVOOUdid0kwdy1oU2dvdUxIX0EwSFpCa0VsVkxlakVGX3dOdGJZUDJVaU1BRnp3TFg0?oc=5","date":"2025-07-17","type":"earnings","source":"nature.com","summary":"Machine learning analysis of drug solubility via green approach to enhance drug solubility for poor soluble medications in continuous manufacturing - nature.com","headline":"Machine learning analysis of drug solubility via green approach to enhance drug solubility for poor soluble medications ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiXEFVX3lxTE1sS3V1ZEktV1pGS1VvMHY5bHR0Y1FGenlPYS03a09QcWd3bTU4czNrZVBHcGtoaUlweElnRHlQQ0UzMGdkTDlBZHhJaVpiOU40VC1lUVljU1lLaEI4?oc=5","date":"2025-03-18","type":"pipeline","source":"EurekAlert!","summary":"WIN Consortium leading the future of precision cancer medicine - EurekAlert!","headline":"WIN Consortium leading the future of precision cancer medicine - EurekAlert!","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixwJBVV95cUxQLW9DaGxUc0M1bEMtVm9aT0hQLTQ0eUNibV80dWdvWW9HX1BJNmRSU3BWNGktWnRLR2p1OWVSanlNQUVfVV9QNzYxa0hyTlVPdThVcENjcE5jNUFCRnA4N3k4WnBoZFZHX0Uwc0dCODBtdGlJZ1lIdHdFTzdPdTRYYTlyM0poeW5VUURMdXRRSmVKbjFkWmJGVXhBUVYyME5lYlpQUDRkV1U3VGVROFZwSHRHek0tR25vUHlsSXRpbEM2WU9kYXVLZGF2bHAxQ0VkMGI1Z3gwbEM3U3V2cTN5eGZkUVlsd0NHRzl1T0xzR0paVk5yblo5Z3ZUN090WkFCdFg5Ni1JMHlWVUJpMXBUUHM5WjhJdlcwUGdic0FJd0dOaUVsNjJ4Y3dGS1Y4bWJDMDNaemVGV0lGNjRFcl9kTk5mOFVpU00?oc=5","date":"2024-06-03","type":"trial","source":"PR Newswire","summary":"Grey Wolf Therapeutics Presents First Clinical Data for GRWD5769, a First-in-Class ERAP1 Inhibitor, at the 2024 American Society for Clinical Oncology (ASCO) Annual Meeting - PR Newswire","headline":"Grey Wolf Therapeutics Presents First Clinical Data for GRWD5769, a First-in-Class ERAP1 Inhibitor, at the 2024 American","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMidkFVX3lxTE5DN1c3SmtwbnhSMmVLSnQ3LXFPcEg3NzVJOHFIdDMyNG05UW8yY1VsZG1JMlVIRi1aZl90YTMzajVUcVJ0SFMzNmxPNzdWMVhrVEZ1dlhyMGNoNGt4MWhiZTd5clZqazVWMU9ZX0lIVnpTSWV2THc?oc=5","date":"2024-05-24","type":"pipeline","source":"Pharmaceutical Technology","summary":"Grey Wolf gets funding to advance antigen modulation technology - Pharmaceutical Technology","headline":"Grey Wolf gets funding to advance antigen modulation technology","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxNS0xJRzdqU1hkaEV3c1BzZHd3V1BvUjFoLWo3aW80SktGMWdNaFBJYkViTE9YbkNxcy03WjNTTU1XbTlVMkdHWWdmeXJobFZIcnVVZ1BlcVJPX2VWenhyV2J4dFdodTBWcDZOTklYNDBvMXpURnZMQnhLa2d5WmcwWkRoTU53Nnd4aGFsY1c2MTU0SmZrUDhQeU14VkRMeXRNdW5nVU9Xal9Sd1JFZGRlMU5CMzNNTGlZSGJuUzhvWQ?oc=5","date":"2024-05-10","type":"trial","source":"The ASCO Post","summary":"Selective Targeting of PARP1 in Early-Phase Study Shows Activity in Breast Cancer - The ASCO Post","headline":"Selective Targeting of PARP1 in Early-Phase Study Shows Activity in Breast Cancer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxQaEZLaFFteU1oQWdHT3BHZmFJS3ZBNnZvaDNYUHRTTzlwNmRsUWlCMXhpZDh1NWRJWUEtY1Flb0hCOEdDclBrUllNYVZkUXFLSFFqRU1faTdkNlJHNXhjTWE1QzVyeWhwaWFRTUFwakxwelUzRm5LV3FUclVUaERNSW96Rnl4d3gyMFRmOXg1MmdXeUx6ZHU5QnZGQ1lNVWFMQVBMNzhlRzZSNXZHSDlpTlpKekRlLWhpRlB4MXZR?oc=5","date":"2019-02-14","type":"trial","source":"Fierce Biotech","summary":"EuroBiotech Report—AstraZeneca clear-out, uniQure data, Grey Wolf, Pathios and CureVac - Fierce Biotech","headline":"EuroBiotech Report—AstraZeneca clear-out, uniQure data, Grey Wolf, Pathios and CureVac","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxNR190X1RLWW1SaVhOa21zbG16WXFCWnZUOWpDczlEckN2MUdjUFVkOGY3RzVjVFdCWFJIMERGT2dvbDhfR3B3c3E3ODNyUTdfRkhHcEc2US1TX0xpYzZaSE9GdWhIWWoxQlJqcnRmcnJsT3UzbGl5eVpGYTFZQVlwUQ?oc=5","date":"2019-02-11","type":"pipeline","source":"labiotech.eu","summary":"Series A to Fund Therapy That Exposes Cancer to Immune System - labiotech.eu","headline":"Series A to Fund Therapy That Exposes Cancer to Immune System","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_1":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}